Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-12-05 00:00:00 ET · period of report 2025-12-03 · accession 0000875320-25-000244 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-05 | 2025-12-03 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $449.99 | -4,500 | 46.8K | -9% | -$2.02M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-03 | S | D | 4,500 | $449.99 | 46,793 | D | — | — | (F3) Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F2) Open market sales reported on this line occurred at a weighted average price of $449.99 (range $449.99 to $450.00). |